(Q40778973)

23 September 2017

Antibody responses to preS components after immunization of children with low doses of BioHepB. (English)

1 reference

23 September 2017

0 references

1

Madalinski K

1 reference

23 September 2017

Sylvan SP

2

1 reference

23 September 2017

Hellström U

3

1 reference

23 September 2017

Mikolajewicz J

4

1 reference

23 September 2017

Zembrzuska-Sadkowska E

5

1 reference

23 September 2017

Piontek E

6

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

23 September 2017

6

1 reference

inferred from page(s)

published in

Vaccine

1 reference

23 September 2017

20

1 reference

23 September 2017

1-2

1 reference

23 September 2017

92-97

1 reference

Global programme for control of hepatitis B infection

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Hepatitis B vaccination and hepatocellular carcinoma in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Functions of hepatitis B surface proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

T- and B-cell recognition of hepatitis B viral antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Immunogenicity of a recombinant Pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Genetic prediction of nonresponse to hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Dissociated antibody responses to the S and pre-S2 regions of the hepatitis B virus after vaccination in hemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Hepatitis B Vaccination in Diabetic Patients: Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900312-7

7 January 2021

10.1016/S0264-410X(01)00312-7

Identifiers

DOI

1 reference

23 September 2017

1 reference